Laboratory Development and Shared Antigenicity of Two Prototype Candidate Citrobacter Freundii Vaccines


  • Ibrahim Shnawa University of Qasim , College of Biotechnology , Department of Biotechnology , Qasim Babylon ,IRAQ
  • Qassim Thewaini University of Qasim , College of Biotechnology , Department of Biotechnology , Qasim Babylon ,IRAQ
  • Abdulrasul ALShibeeb Babylon Board of Health, Central Public Health Laboratory,Babylon,Hillah,IRAQ


Antibody, Antisera, Shared antigenicit, Agglutinin, Absorption.


Cirobacter  freundii are currently standing  as a  newly emerged human pathogen causing several infection types .It may  take an outbreak pattern of  nosocomial  infectious disease. Thus,  a  prototype candidate Citrobacter  freundii  human uro-pathogen were aimed to be  laboratory developed in two versions .The first  was heat killed intact[CFKV] and the second was  stealth live  cell wall defective[CFSLV] vaccines. Both versions  were found to be; safe ,immunogenic  and effective  on  lapin immune and  challenge models. The immune  efficacy  was up to 80% for CF SLV  and 60% for the CFKV vaccines. CFKV and CFSLV  vaccines  were with no mortality but with mild short lasting  morbidity. The criteria of the  laboratory developed  C. fruendii vaccines were matching that of typhoid vaccine Ty21a.The stealth FCSLV of  freundii vaccine has shown shared  antigenicity with CFKV vaccine version. Such shared antigenicity was found to be of bilateral nature  both in quantitative and qualitative terms. CFKV and CFSLV vaccines  induced humoral antibody responses  which  may be of Th2 dependent B cell responses. T cell responses are far from being operable in  the immune  efficacy of these vaccines, since  C .fruendii are neither obligate nor facultative intracellular parasites . Vaccine lapin  cross challenge models  are waiting to be explored in a  future work.


. J.G.Whalen,T.W. Mully , J.C. English . “Spontaneous Citrobacter fruendii infection in an immunocompramized patients . ” Arch.dermatol, 143(1), 124-125,2007.

. L-H.Liu.,N-Y.Wang ,A.Y.Wu ,C.C.Lin, C-M.Lee, C-P.Liu, “Citrobacter fruendii bacterium:Risk factors of mortality and prevalence of resistance genes. ” J.Microbiol.Immunol.Inf . , 51 , 565-572.

. N.Kamada , K.Sakamoto , J.L.Puente , G.Nunez , “ Humoral immunity in gut selectivity target phenotypically virulent attaching and facing bacteria for intraluminal elimination. ” Cell.Host.and Microbe. ,17,617-627 ,2015.

. M.T.Anderson , L.A.Mitchell , L.Zhao , L.T.Mobley, “Citrobacter fruendii fitness during blood stream infection ” .Sci.Rep. ,8,11792,2018.

. M.F.Darwish, “Exo-polysaccharide vaccine from Citrobacter fruendii induce immunity against inflectional pathogen ” .Kuf.Uni.J.Biol. , 2 ,150-160 , 2017.

. A.A.ALThahab. “Immunological effects of Citrobater fruendii ell free culture in rabbits. ” Baby.Uni.J. ,2(23),605-609 ,2015.

. C.P.Simmons , S.Clart , Ghaem-Maghami. Et al., “Control role for B lymphocyte and CD4+ T cells in immunity to infection with attaching effacing pathogen C.rodentium. ” Inf.Imm.71(9) ,5077-5086 ,2003.

. Q.N.Thewaini. “Biology of Cell wall Defective Microbes From Persistent Pyuria And Haematuria. ” Ph.D. , Thesis , Babylon University, IRAQ, 2002.

. J.J.Sharp, L. Dienes , “Carbohydrate containing antigens from L.forms Proteus. ” J. Bateriol. 78,343-351 ,1959.

. M.A.N.ALShahery,I.M.S.Shnawa, “The immunological adjuvanicity of sunflower oil. ” Vet.Med.Giza. ,37(2) ,291-298 , 1989.

. NIH., understanding Vaccines. , Publication Number ,98-4219, 24-25 , 1998.

. S.A.Plotkin ,Phrma Fact Book. ,109 Pages,52-64 , 2012.

. C.D. Stevens ,Clinical Immunology And Serology:A Laboratory Perspective,3rd.ed . , Philadelphia :F.A.Davis Company ,108-116,137-142.2010.

. R.Sakazaki,T.J.Donovan,” Serology,epidemiology of Vibrio cholera, V. mimicus. ” , Methods In Microbiology, ASM ,1984.16:271-289.

. I.M.S.Shnawa, “A Study on the serogrouping of Vibrio cholera[NAG]. ” Zag.Vet.J.IV(A),161-169,1982.

. A.Collioud ,S.A. Rothen , G. Dietrich, “Developing and manufacturing of attenuated live bacterial vaccines . ” , Bio.Pharm.Int. , 6 ,Suppl ,1-12 , 2008.

. K.P.Rangan, N. Rangan , “Citrobacter :An emerging care associated urinary tract pathogen” .Urol.Ann.5(4):313-314.,2013.

. S.D.Gobal , S.Raj, “ incidence of Citrobacter urinary tract infection in type II diabetes and its relationship to glycemia control . ” Int.Cont.Med.Res. , 4(1) ,60-62.

. L.Bery ,M.Brigl , M.B.Brenner, “ CD4+ T cell effector function and co-stimulatory requirements essential for surviving mucosal infection with attaching effacing pathogen. ” Inf.Immun.74(1) ,673-681 , 2006.

. I.M.S.Shnawa,Q.N.O.Thewaini, “Lapin evaluation parameters for the prototype experimental stealth bacterin prepared from human uropathogen . ” Int.J.Sci. :Basic.Appl.Res.35(1):12-18.,2017.

. B.Adler, Leptospira and Leptospirosis. , Springer,280,2014.

. A.Rabson, I.Roitt ,P.J. Delves . Really Essential Medical Immunology 2nd ed. USA, Blackwellpublications,2005,50-61.

. M.W.Steward . Antibodies:Their Structure And Function.N.Y.Chapman And Hall .1984,55-60.

. S.H.E.Kaufmann et al.,TBVA2020. Advancing Tuberculosis Vaccines from discovery to clinical development.Front. Immunol.8:1203.




How to Cite

Shnawa, I., Thewaini, Q., & ALShibeeb, A. (2019). Laboratory Development and Shared Antigenicity of Two Prototype Candidate Citrobacter Freundii Vaccines. International Journal of Sciences: Basic and Applied Research (IJSBAR), 43(1), 22–29. Retrieved from